Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

By Zacks7 days ago

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.47 per share when it actually produced a loss of $0.48, delivering a surprise of -2.13%.


Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Protagonist Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.19 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 65.04%. This compares to year-ago revenues of $3.65 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Continue read on